Bai, Ming,
Wang, Xiaolong,
Zhang, Huixue,
Wang, Jianjian,
Lyaysan, Gaysina,
Xu, Si,
Tian, Kuo,
Wang, Tianfeng,
Li, Jie,
Wang, Na,
Lu, Xiaoyu,
Zhang, Xiaoming,
Wang, Lihua (2022) results showed that they were more likely to contribute to the
poor prognosis, which could be hardly
Beylerli, Ozal,
Beilerli, Aferin,
Shumadalova, Alina,
Wang, Xiaoxiong,
Yang, Mingchun,
Sun, Hanran,
Teng, Lei (2022) a highly invasive growth pattern, which creates
poor prospects for patient survival. Chemotherapy
KHABIBOV, M.,
GARIFULLIN, A.,
KHAMITOV, F.,
KHALIKOVA, L.,
BOUMBER, Y.,
KHADDOUR, K.,
FERNANDEZ, M.,
KUZNETSOVA, N.,
KIT, O.,
KHARIN, L. (2022) and is associated with a
poor
clinical prognosis. Despite the progress in the understanding of the
molecular
Asadi-Pooya, AA,
Trinka, E,
Brigo, F,
Hingray, C,
Karakis, I,
Lattanzi, S,
Valente, KD,
Contreras, G,
Turuspekova, ST,
Kishk, NA,
Aljandeel, G,
Farazdaghi, M,
Lopez, YC,
Kissani, N,
Triki, C,
Kramer, G,
Surges, R,
Mesraoua, B,
Yu, HY,
Daza-Restrepo, A,
Alsaadi, T,
Al-Asmi, A,
Kutlubaev, MA,
Pretorius, C,
Jusupova, A,
Khachatryan, SG,
Ranganathan, LN,
Ashkanani, A,
Tomson, T,
Gigineishvili, D (2022) this condition were considered to be those with
poor anti-seizure medication (ASM) adherence, frequent tonic
Ahmad, S.,
Abbas, M.,
Ullah, M.F.,
Aziz, M.H.,
Beylerli, O.,
Alam, M.A.,
Syed, M.A.,
Uddin, S.,
Ahmad, A. (2022) RNA (NKILA) associate with lymph node metastasis and
poor prognosis of individual cancers. The role
Wu, JN,
Al-Zahrani, A,
Beylerli, O,
Sufianov, R,
Talybov, R,
Meshcheryakova, S,
Sufianova, G,
Gareev, I,
Sufianov, A (2022) -grade gliomas remains
poorly known.
Methods: We retrieved published articles from the PubMed, the Cochrane
Han, Dayong,
Teng, Lei,
Wang, Xiaoxiong,
Zhen, Yunbo,
Chen, Xiaofeng,
Yang, Mingchun,
Gao, Ming,
Yang, Guang,
Han, Mingyang,
Wang, Ligang,
Xu, Jiajun,
Li, Yue,
Shumadalova, Alina,
Zhao, Shiguang (2022) Background: Glioma is the most common primary brain tumor in adults with
poor prognosis. The glioma
Xu, Dongxiao,
Zheng, Bingjie,
Wu, Qiaowei,
Yao, Jinbiao,
Ilyasova, Tatiana,
Beilerli, Aferinc,
Shi, Huaizhang (2022) (51.6%), fair in 4 patients (6.0%), and
poor in 1 patient (1.5%); the overall rate of favorable
